Last reviewed · How we verify

penpulimab combined with anlotinib

Tang-Du Hospital · FDA-approved active Small molecule Quality 5/100

penpulimab combined with anlotinib is a Small molecule drug developed by Tang-Du Hospital. It is currently FDA-approved.

At a glance

Generic namepenpulimab combined with anlotinib
SponsorTang-Du Hospital
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about penpulimab combined with anlotinib

What is penpulimab combined with anlotinib?

penpulimab combined with anlotinib is a Small molecule drug developed by Tang-Du Hospital.

Who makes penpulimab combined with anlotinib?

penpulimab combined with anlotinib is developed and marketed by Tang-Du Hospital (see full Tang-Du Hospital pipeline at /company/tang-du-hospital).

What development phase is penpulimab combined with anlotinib in?

penpulimab combined with anlotinib is FDA-approved (marketed).

Related